Clinical trial
Relvar 100 Ellipta Special Drug Use Investigation (COPD, Long-term)
NCT03219255 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Relvar 100 Ellipta Special Drug Use Investigation (COPD, Long-term)
- Lead sponsor
- GlaxoSmithKline
- Phase
- Observational
- Overall status
- Completed
- Start date
- August 30, 2017
- Completion date
- March 30, 2021
- Enrollment
- 1,047 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.